Clinical Trial Update: NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 NeoOPTIMIZE trial evaluating upfront switching between mFOLFIRINOX and Gemcitabine/Nab-Paclitaxel before surgery for resectable to unresectable pancreat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Nab-paclitaxel (paclitaxel protein-bound)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-14